Novo Nordisk (0QIU) Receives a Hold from Jefferies
In a report released today, Michael Leuchten from Jefferies maintained a Hold rating on Novo Nordisk, with a price target of DKK270.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Leuchten is ranked #11213 out of 12125 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a DKK294.54 average price target.
Based on Novo Nordisk’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of DKK79.14 billion and a net profit of DKK26.89 billion. In comparison, last year the company earned a revenue of DKK85.68 billion and had a net profit of DKK28.23 billion
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.
Read More on GB:0QIU:
Disclaimer & DisclosureReport an Issue
- Morning Movers: Globalstar climbs following deal to be acquired by Amazon
- Novo Nordisk partners with OpenAI to speed drug development
- Novo Nordisk says EMA approved update to Wegovy injection product information
- Moderately bullish activity in Novo Nordisk with shares up 0.2%
- Novo Nordisk says higher dose Wegovy injection available nationwide
